Susquehanna International Group, LLP Krystal Biotech, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $2.52 Million - $3.08 Million	14,400 Added 13.35%	122,300 $22.2 Million
Q2 2024 Aug 15, 2024	SELL	$153.12 - $183.64 $5.68 Million - $6.81 Million	-37,100 Reduced 25.59%	107,900 $19.8 Million
Q1 2024 May 07, 2024	SELL	$108.01 - $179.35 $1.16 Million - $1.92 Million	-10,700 Reduced 6.87%	145,000 $25.8 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $6.38 Million - $8.53 Million	66,500 Added 74.55%	155,700 $19.3 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $2.09 Million - $2.51 Million	19,300 Added 27.61%	89,200 $10.3 Million
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $102,024 - $169,416	-1,300 Reduced 1.83%	69,900 $8.21 Million
Q1 2023 May 16, 2023	BUY	$72.39 - $84.27 $3.58 Million - $4.16 Million	49,400 Added 226.61%	71,200 $5.7 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $220,990 - $279,650	-3,500 Reduced 13.83%	21,800 $1.73 Million
Q3 2022 Nov 14, 2022	BUY	$64.85 - $82.4 $499,344 - $634,480	7,700 Added 43.75%	25,300 $1.76 Million

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.51B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.